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Malaria is a major global health threat, with nearly half the world’s population at risk of
infection. Given the recently described delayed clearance of parasites by artemisinincombined therapies, new antimalarials are needed to facilitate the global effort toward
elimination and eradication. NPC1161 is an 8-aminoquinoline that is derived from
primaquine with an improved therapeutic profile compared to the parent compound.
The (R)-(−) enantiomer (NPC1161B) has a lower effective dose that results in decreased
toxic side effects such as hemolysis compared to the (S)-(+)-enantiomer, making it a
promising compound for consideration for clinical development. We explored the effect
of NPC1161B on Plasmodium falciparum oocyst and sporozoite development to evaluate
its potential transmission-blocking activity viz. its ability to cure mosquitoes of an ongoing
infection. When mosquitoes were fed NPC1161B 4 days after P. falciparum infection, we
observed that total oocyst numbers were not affected by NPC1161B treatment. However,
the sporozoite production capacity of the oocysts was impaired, and salivary gland
sporozoite infections were completely blocked, rendering the mosquitoes non-infectious.
Importantly, NPC1161B did not require prior liver metabolism for its efficacy as is required
in mammalian systems, suggesting that an alternative metabolite is produced in the
mosquito that is active against the parasite. We performed liquid chromatography–mass
spectrometry (LC-MS)/MS analysis of methanol extracts from the midguts of mosquitoes
fed on an NPC1161B (434.15 m/z)-treated blood meal and identified a compound with
a mass of 520.2 m/z, likely a conjugate of NPC1161B or an oxidized metabolite. These
findings establish NPC1161B, and potentially its metabolites, as transmission-blocking
candidates for the treatment of P. falciparum.
Keywords: Plasmodium, NPC1161B, malaria, 8-aminoquinoline, transmission-blocking, metabolite analysis
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INTRODUCTION

in glucose-6-phosphate dehydrogenase (G6PD)–deficient
individuals and may elicit exaggerated responses in NADH
methemoglobin reductase-deficient individuals and pose
dangers for pregnant women (Hill et al., 2006). Due to these
dangers, these drugs cannot provide antimalarial protection for
everyone, leaving the need for a safe and efficacious antimalarial
(Nanayakkara et al., 2008).
Primaquine and tafenoquine are used as racemic mixtures
for the treatment of malaria. Another 8AQ, 8-[(4-amino1 - m e t hy l but y l ) am i n o ] - 6 - m e t h ox y - 4 - m e t hy l - 5 - [ 3 , 4 dichlorophenoxy]quinoline succinate (NPC1161, WR 233078)
in racemic form (NPC1161C) has shown excellent antimalarial
activity in animal models (Nanayakkara et al., 2008). In a P.
berghei model, NPC1161C cleared blood stage parasites and
was curative within 3 days of oral treatment at 1 mg/kg/day;
by contrast, tafenoquine required 16 mg/kg/day for 3 days, and
primaquine was ineffective even at 64 mg/kg/day (Nanayakkara
et al., 2008). In the mouse causal prophylaxis model, NPC1161B
is active at 1 mg/kg/day for 3 days, while tafenoquine and
primaquine require 3 and 20 mg/kg/day for 3 days, respectively
(Pybus et al., 2013; Marcsisin et al., 2014). NPC1161C has also
shown potent radical curative activity against Plasmodium
cynomolgi infection in rhesus monkeys (primaquine index 4.8)
(Davidson et al., 1981). In some cases, a single enantiomer can
provide a better therapeutic index than the racemic mixture
(Nguyen et al., 2006). The (R)-(−)-enantiomer (NPC1161B)
has less hemolytic toxicity in mice and dogs, and more activity
against several different parasites in animal models than the
racemate (NPC1161C) or the (S)-(+)-enantiomer (NPC1161A)
(Tekwani and Walker, 2006; Nanayakkara et al., 2008).
Studies have documented the importance of human
cytochrome P450 (CYP) enzymes in the metabolism of 8AQ
(Ganesan et al., 2009; Myint et al., 2011; Marcsisin et al.,
2014). Specifically, enzyme CYP 2D6 has been suggested to
play a critical role in the metabolism of primaquine, as well as
tafenoquine and NPC1161B, into potential active metabolites
(Bennett et al., 2013; Pybus et al., 2013; Marcsisin et al., 2014).
Furthermore, NPC1161B had no antimalarial activity in CYP
2D6-knockout mice infected with P. berghei (Marcsisin et al.,
2014). However, little is known about the metabolism of 8AQ or
its potential metabolites in non-vertebrate systems. Although
metabolism of other compounds, such as pyrethroids, has
been observed in the mosquito vector, no studies have shown
the metabolism of 8AQ by mosquitoes (Ibrahim et al., 2016).
NPC1161B can prevent exflagellation events in in vitro P.
falciparum gametocyte cultures, and oocyst development and
sporogony in P. berghei and P. falciparum in vivo systems,
suggesting that NPC1161B does not need CYP-mediated
metabolism to derive antimalarial transmission-blocking
activity (Delves et al., 2012).
Here, we report the use of NPC1161B to disrupt P. falciparum
sporogonic development in Anopheles stephensi mosquitoes
with an ongoing P. falciparum infection. Additionally, we
provide evidence that NPC1161B metabolites are produced in
the mosquito midgut following ingestion of NPC1161B-treated
blood meal over the 48-h period of blood digestion.

Malaria is a devastating disease that globally affects over 200
million people annually and caused over 435,000 deaths in
2017, mostly in children under the age of five. Despite the
significant progress made in recent years, global malaria
control has stagnated between 2015 and 2017 (WHO, 2017).
Plasmodium falciparum, Plasmodium vivax, Plasmodium
ovale, Plasmodium malariae, and Plasmodium knowlesi are
the causative agents of malaria in humans, with P. falciparum
being the most lethal. Plasmodia are transmitted by anopheline
mosquito vectors. When the mosquito takes a blood meal,
Plasmodium sexual stage gametocytes transition into male and
female gametes, which fertilize and develop into the motile
ookinete. Ookinetes invade the mosquito midgut to form an
oocyst, which functions as the sporozoite production site.
The development of each oocyst leads to the production of
thousands of sporozoites, which then invade the salivary glands
of the mosquito, making the mosquito capable of transmitting
parasites during its next blood meal (Al-Olayan et al., 2002;
Zollner et al., 2006; Nacer et al., 2008).
Current front-line malaria treatments focus on eliminating
the asexual blood stages of the parasite; however, even after
asexual parasites are eliminated, the gametocytes can persist,
allowing transmission to new mosquito vectors (Tangpukdee
et al., 2008). A natural bottleneck in parasite number occurs in
the mosquito, with a minimum in parasite number occurring
in the oocyst stage, making the sexual stage an appealing target
for drug intervention to prevent transmission (Vaughan et al.,
1992; Porter-Kelley et al., 2006). As the current antimalarials
become less effective in Africa and Southeast Asia, alternative
antimalarial drugs are needed (German and Aweeka, 2008;
Abdul-Ghani et al., 2017). The 8-aminoquinolines (8AQ)
have shown potential to fill this need and act as transmissionblocking drugs for malaria (Tekwani and Walker, 2006; WHO,
2011; White, 2013).
The 8AQ are the only class of drug that has been approved
by the Food and Drug Administration (FDA) to clear dormant
hepatic hypnozoites in patients with P. vivax and P. ovale.
They are also effective against Plasmodium asexual and sexual
blood stages and mosquito stages (Tekwani and Walker,
2006). This versatility in targeting allows these drugs to act as
prophylactics or as treatment/transmission-blocking agents
during Plasmodium infections (Tekwani and Walker, 2006).
For example, primaquine is used as an effective prophylaxis
for all forms of malaria, as a treatment for P. vivax and P. ovale
infections, and as a transmission interrupter for P. falciparum
(Baird and Hoffman, 2004; Hill et al., 2006; Tekwani and Walker,
2006; WHO, 2011; White, 2013). Tafenoquine (WR 238605), a
primaquine derivative that was approved by the FDA in 2018
for the radical cure of relapsing malaria, has also been shown
to prevent the transition of P. vivax, P. falciparum, Plasmodium
yoelii, and Plasmodium berghei gametocytes to gametes and
inhibit sporozoite production of P. vivax and P. falciparum
(Peters et al., 1993; Ponsa et al., 2003; Walsh et al., 2004).
However, these 8AQ induce pronounced hemolytic effects
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RESULTS

On day 8 after infection, mosquito midguts were dissected and
either stained with 0.1% mercurochrome for oocyst enumeration
or probed with anti-PfCSP antibody and 4′,6-diamidino-2phenylindole (DAPI) nuclear stain. We observed that NPC1161B,
when administered at the time of infection, significantly reduced
oocyst intensity (P = 0.0040; two-tailed t-test) in the mosquitoes
(Figure 1A); this is akin to what has been described previously
for tafenoquine; however, NPC1161B treatment at day 4 postinfection did not show a significant difference (P = 0.4935; twotailed t-test) between the number of oocysts observed on the
control- and NPC1161B-treated midguts (Figure 1B), showing
that once oocyst development has been initiated (between 24 and
48 h post-infection), NPC1161B does not affect oocyst numbers
(Ponsa et al., 2003). We did observe a trend toward a reduction

NPC1161B Has A Significant Effect On
Oocyst Development

We first determined whether NPC1161B had an effect on oocyst
development, and whether metabolism by a vertebrate host
was essential for such effects. To address these questions, An.
stephensi mosquitoes were infected with P. falciparum using
a standard membrane feeding assay (SMFA). A dose of 10 μM
NPC1161B was either provided in the infectious blood meal or
4 days later in a second uninfected blood meal. Previous work
demonstrated that the 10 μM dose could inhibit P. falciparum
gametocyte exflagellation and subsequent oocyst development
when added to in vitro parasite cultures (Delves et al., 2012).

FIGURE 1 | NPC1161B (10 μM) can significantly reduce oocyst number and reduces oocyst size. (A) NPC1161B (10 μM) or carrier solvent was administered
at the time of infection. The midgut oocyst number was enumerated at day 8 post-infection; a representative replicate is shown. (B) NPC1161B (10 μM) or
carrier solvent was administered at day 4 post-infection. The oocyst number was enumerated at day 8 post-infection; a representative replicate is shown.
(C–D) NPC1161B (10 μM) or carrier solvent was administered at day 4 post-infection, and oocyst diameter was evaluated at day 8 post-infection. Representative
experiments are shown. (N = 20 mosquitoes/group).
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and the resulting ions analyzed in full scan mode (35–500 m/z)
by the third quadrupole. Injections of NPC1161B were repeated
in an iterative process to determine the optimal CID energies and
resulting fragment ions from the parent drug that could be used
to identify metabolites in the blood meal (Figure 3).
Midguts (n = 10) from uninfected An. stephensi and An.
gambiae mosquitoes previously fed a blood meal containing
NPC1161B (10 µM) were dissected at 48 h post-feeding into
cold methanol for metabolite extraction and subsequent analysis
by LC-MS. Potential metabolites of NPC1161B produced in
mosquitoes were then determined by precursor ion scanning
using a QqQ-MS. In this mode, the first quadrupole was set to
full scan mode (100–600 m/z), the second quadrupole set to
fragmentation by CID at 42 eV, and the third quadrupole was
set to detect only the fragments generated from NPC1161B
with m/z of 203.2, 215.1, or 334.0. In this way, only compounds
that gave rise to one or more of these fragments were detected.
The extracted ion chromatogram (XIC) for the sum of all three
product ions shows a number of peaks with low intensity that were
not found to stem from metabolized NPC1161B, likely resulting
from low abundance of only one or two product ions. However,
only a single intense peak was observed and determined to likely
be a metabolite of NPC1161B (Figure S1). This observation was
based on two factors: 1) all three fragment ions were observed
and found to stem from a single peak with a mass of 520.2 m/z,
and 2) the parent ion observed showed a distinctive isotope
spacing that results from chlorine-containing compounds, such
as NPC1161B, when analyzed by mass spectrometry.
Having found a potential metabolite of NPC1161B in
mosquito midguts, we further characterized this compound
using high resolution LC-MS. Both the NPC1161B standard and
the previously analyzed midgut metabolite extract were analyzed
using quadrupole time-of-flight mass spectrometry (Q-ToF-MS),
which produces higher resolution data than the QqQ-MS system
used previously. The mass spectra of both the parent compound
and resulting metabolite showed the distinctive chlorine isotope
spacing expected (Figure S2), suggesting that the ion observed
in the blood meal was likely a metabolite of NPC1161B produced
in the mosquito midgut. Both ions were then subjected to
fragmentation by CID, and the resulting patterns showed a high
degree of similarity, providing further evidence that the two
compounds were related and that the metabolite originated from
NPC1161B (Figure 4, summarized in Table 1). Additionally, to
confirm that the observed metabolite from midgut extracts was
not the result of direct metabolism by red blood cells (RBCs),
as has been seen recently for the related 8-AQ primaquine, we
analyzed extracts from uninfected RBCs that were incubated with
NPC1161B alone. RBCs were incubated with 10 µM NPC1161B
for up to 48 h, then extracts were prepared and analyzed as before
(Fasinu et al., 2019). We did not observe the formation of the
metabolite previously extracted from midguts (520.2 m/z), and
in fact, we saw no change in NPC1161B abundance at any of the
time points analyzed (1, 6, 24, and 48 h).
We next attempted to determine the structure of the NPC1161B
metabolite. The structure and resulting fragment ion m/z data
from NPC1161B were submitted to MetFragWeb, an online tool
that performs in silico fragmentation and structure prediction

in oocyst diameter with 10 μM NPC1161B treatment on day 4
post-P. falciparum infection; however, the statistical significance
of this trend was inconsistent (Figures 1C, D).

NPC1161B Affects Sporozoite
Development In Oocysts

Having shown that NPC1161B affects oocyst size but did not
alter the number when given 4 days post-infection, we set out
to study whether NPC1161B would have an effect on the oocyst
to sporozoite transition. We administered NPC1161B (10 µM)
by membrane feeding at day 4 post-infection and monitored
the phenotype of oocyst development using a whole-mount
midgut immunofluorescence assay and salivary gland sporozoite
enumeration. Oocyst development and maturation on the basal
midgut wall are intrinsically asynchronous. As expected, at day
11 post-infection, oocysts that developed without exposure to
NPC1161B had already released sporozoites (Figures 2A, B). This
was not observed in mosquitoes exposed to NPC1161B (Figures
2C, D), suggesting that oocyst maturation was arrested. We also
observed a wider range of oocyst diameters in the NPC1161Btreated mosquitoes than in the control-treated mosquitoes
(Figures 2A–D), thus corroborating our previous data (Figures
1C, D). DAPI staining of nuclei indicated that, regardless of
size, punctate or partitioned DNA was readily observed even in
smaller oocysts in the treatment group, indicative of sporoblast
initiation (Ganter et al., 2017). However, we did observe weaker
PfCSP staining in NPC1161B-treated midguts compared with
the carrier-treated controls, suggesting that there was a defect
in oocyst maturation or typical developmental pathways. At
day 14 post-infection (day 10 post-NPC1161B treatment),
when the majority of oocysts should have already ruptured, the
salivary glands were dissected and processed, and the number of
sporozoites per gland was enumerated. Three blinded replicate
treatment cohorts demonstrated a significant reduction (P <
0.001 for carrier vs. each NPC1161B-treated replicate; twotailed t-test) in sporozoite number in mosquitoes fed on blood
with NPC1161B 4 days post-infection, as compared with control
mosquitoes (Figure 2E).

A Novel NPC1161B Metabolite Is
Produced In The Mosquito

In light of the finding that NPC1161B is effective at preventing
P. falciparum development in the mosquito without prior
metabolism of the compound by mammalian host CYP enzymes,
we hypothesized that there is metabolism of NPC1161B in the
mosquito midgut. To understand whether mosquito metabolism
of NPC1161B contributes to parasite elimination, we used liquid
chromatography–mass spectrometry (LC-MS) to evaluate the
metabolites produced in the mosquito midgut after ingestion of a
blood meal and exposure to NPC1161B.
To identify potential metabolites of NPC1161B from the
midgut, we first analyzed the parent drug by product ion scanning
using a triple quadrupole mass spectrometer (QqQ-MS). In this
mode, the first quadrupole was used to select for NPC1161B
(434.15 m/z) eluting from the column, which is fragmented by
collision-induced dissociation (CID) in the second quadrupole,
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FIGURE 2 | NPC1161B-derived metabolites block sporozoite development. Mosquitoes were given carrier solvent alone (A-B) or NPC1161B (10 µM) (C-D) at
day 4 post-infection. Midguts were dissected on day 11 post-infection. The midguts were probed with anti-P. falciparum circumsporozoite protein to identify fully
formed sporozoites and stained with DAPI to permit visualization of individual sporozoite segmentation. The dotted white lines demarcate the boundaries of oocysts
captured in the field of view. The white arrows point to a group of sporozoites that were released from a burst oocyst and found fixed to the outside of the midgut.
(E) NPC1161B (10 µM) or carrier solvent was administered to mosquitoes at day 4 post-infection; salivary glands were dissected, and sporozoites were counted at
day 14 post-infection. The reduction in sporozoite number for each replicate of NPC1161B treatment (N = 25) as compared to the carrier solvent treatment (N = 25)
was found to be statistically significant by ANOVA (P < 0.0001).

(Ruttkies et al., 2016). The algorithm takes as input a structure and
fragment ions and produces formula and predicted structures for
each fragment ion within a given tolerance. Using the output of
this search, we were able to putatively match a number of high
abundance fragment ions from NPC1161B with structures and
formulas (Figure 5; Table 1; Table S1). Furthermore, many of
these fragment ions were also present in the metabolite observed
in the midgut extract. While we could not elicit an accurate

Frontiers in Pharmacology | www.frontiersin.org

structure of the metabolite, the major fragment ions of the core
8AQ structure were present. The observed mass of 520.2 m/z for
the NPC1161B metabolite is significantly higher than the parent
compound at 434.15 m/z, suggesting this may be a conjugate of
NPC1161B, or perhaps a conjugate of an oxidized metabolite.
At this stage, structural identification is not possible using
conventional methods. Further analysis by NMR spectroscopy is
needed to fully elicit a structure for this metabolite.
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FIGURE 3 | Analysis of NPC1161B standard by LC-QqQ-MS. Extracted ion chromatogram for NPC1161B standard (A) and the resulting product ion scan (B).
Product ion scanning was used to select fragment ions of NPC1161B for downstream precursor ion scanning to determine metabolites of NPC1161B extracted
from mosquito midguts post-feeding. A 1 µl injection of 100 pg/µl was subjected to fragmentation at 42 eV, where Q1 was set to the parent ion (434.15 m/z), and
Q3 was set to obtain a full scan from 35 to 500 m/z. Three ions were selected for use in precursor ion scans: 203.1, 215.1, and 334.0 m/z.

FIGURE 4 | Fragmentation analysis of NPC1161B standard and metabolite by LC-QToF-MS. Mass spectra for NPC1161B standard (A) and the metabolite
identified from mosquito midgut extracts post-blood meal (B) after fragmentation at 42 eV. A number of peaks were found to be shared by both compounds (see
Table 1).

Frontiers in Pharmacology | www.frontiersin.org

6

October 2019 | Volume 10 | Article 1265

Hamerly et al.

NPC1161B Inhibits Plasmodium Sporogony

antimalarial effects of NPC1161B through its ability to prevent
P. falciparum exflagellation and subsequent oocyst development
when added directly to gametocytemic blood (Delves et al.,
2012). Our study extends these findings to shed new light on
the utility of NPC1161B as a transmission-blocking antimalarial
that can also be effective when delivered after the establishment
of infection in the mosquito. The varied DAPI nuclear staining
observed (Figures 2A–D), the difference in oocyst size (Figures
1C, D), and the significant difference in sporozoite production
(Figure 2E) in the NPC1161B-treated mosquitoes compared
with control-treated mosquitoes suggest that NPC1161B
disrupts sporozoite development in the oocyst when given at
10 µm. By preventing the development of sporozoites in the
oocyst, no sporozoites can be released into the hemolymph
to invade the salivary glands, and the mosquito can no longer
transmit the parasite. This suggests that NPC1161B would not
only be effective in blocking transmission from patients infected
with Plasmodium by killing gametocytes but may also be effective
when uninfected individuals are fed upon by mosquitoes that are
carrying parasites as has been shown previously with the 8AQ
tafenoquine (Ponsa et al., 2003).
The mechanism of action of the 8AQ like NPC1161B
remains unclear, but it is likely that they exert their antimalarial
effects by generating reactive oxygen species and/or interfering
with the parasite’s electron transport chain. Historically, these
effects were believed to be due to the metabolites from the
8AQ (Grewal, 1981). However, previous work with NPC1161B
suggested that it could affect P. falciparum without any prior

TABLE 1 | Fragment ion, predicted formula, and the relative intensity for each
ion from NPC1161B and its metabolite.
Fragment
m/z

Predicted formula

% Rel. Int.
NPC1161B
(434.14 m/z)

% Rel. Int.
metabolite
(520.13 m/z)

70.08
80.95
84.08
86.10
175.09
187.06
203.08
215.12
290.01
303.04
318.01
334.03
345.06
349.05
360.04
372.05
375.07

[C5H10]+
–
[C5H11N-H]+
[C5H12N]+
[C10H10N2O+H]+
[C11H9NO2]+
[C11H10N2O2+H]+
[C13H14N2O+H]+
–
–
–
[C17H12Cl2NO2+2H]+
[C18H14Cl2N2O]+H]+
[C17H13Cl2N2O2+2H]+
[C18H14Cl2N2O2]+
–
[C19H17Cl2N2O2]+

11.1
0.9
17.7
8.0
8.6
3.8
19.5
11.9
1.3
1.6
2.2
4.1
51.2
22.0
22.0
1.0
100

16.3
2.3
–
–
6.23
2.2
16.7
8.35
1.3
3.5
5.3
1.9
12.0
4.0
13.5
2.5
100

DISCUSSION
Transmission-blocking drugs are an essential weapon in
the fight to eliminate and eradicate malaria (The malERA
Refresh Consultative Panel On Basic Science And Enabling
Technologies, 2017). Previous work has established the direct

FIGURE 5 | Mass spectrum showing the fragmentation pattern of NPC1161B annotated with the m/z and predicted chemical formula with structure. The structure
of NPC1161B is shown with the red region denoting the predicted fragment that matches to a given ion.
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NPC1161B has already shown efficacy in both P. falciparum
and P. berghei, so it will be important to extend these findings,
particularly to P. vivax (Delves et al., 2012). Using a drug that
can target multiple Plasmodium species would be advantageous
in the field, especially in areas where cases of malaria are not
diagnosed by species-specific rapid diagnostic tests or other
species-specific methods.
Overall, there remains a critical need for effective antimalarials
on the path toward disease eradication. Currently utilized
antimalarials such as chloroquine-, mefloquine-, pyrimethamine-,
and artemisinin-based combination therapies are not safe for all
patients, neither are they efficacious due to the increasing levels
of resistance among parasites (German and Aweeka, 2008; AbdulGhani et al., 2017). By disrupting sporozoite development in the
oocyst with NPC11161B treatment, sporozoites can no longer
invade the salivary glands, therefore ending the cycle of parasite
transmission. These findings make NPC1161B a promising
compound for further investigation to fill the need for new
transmission-blocking antimalarials.

metabolism (Delves et al., 2012). Here, we expanded on
this concept and found that NPC1161B can be metabolized
uniquely in An. stephensi and An. gambiae mosquitoes
without the need for mammalian CYP enzymes to activate
its antimalarial functions. The persistence and dissemination
of the active metabolites we observed following ingestion of
an NPC1161B-treated blood meal to affect oocysts maturing
on the midgut wall are provocative. Interestingly, there was
no evidence of the parent compound present in the dissected
midguts, suggesting full metabolism, or potentially excretion,
within 48 h post-feeding. Determination of the structures of the
NPC1161B metabolites identified here (Figure 4) could lead
to the chemical synthesis of these compounds for subsequent
testing in liver stage assays for P. falciparum and P. vivax, as
well as for use in murine malaria in vivo models, to determine
if potency is maintained while subsequently reducing toxicity
(Roth et al., 2018).
As the 8AQ are generally associated with hemolytic toxicity
in G6PD-deficient humans, it would be ideal to find a metabolite
that could safely be administered (Hill et al., 2006; Nanayakkara
et al., 2008). An additional option to reduce potential toxicity
with the parent NPC1161B compound would be to add a
modification to prevent activation until it is transferred from
the human bloodstream to the mosquito midgut. Recent work
has established the feasibility of inserting light-regulated photo
switches into drug molecules; in the presence of this photo switch,
the compound would only become active when transferred
from the darkness of the human bloodstream to the semitransparent conditions of the mosquito midgut (Nevola et al.,
2013; Paaijmans and Fernàndez-Busquets, 2014). Alternatively,
infected mosquitoes could be treated directly with NPC1161B,
thereby avoiding the potential for toxic side effects in the human
host. One potential delivery strategy would be to pretreat
mosquito resting surfaces with the compound. Mosquitoes are
known to take up atovaquone through their legs, leading to a
decrease in or even the absence of oocysts following a subsequent
P. falciparum blood meal (Tenywa et al., 2017; Maia et al., 2018).
However, other compounds such as pyrimethamine are not taken
up through the cuticle, and uptake through the legs may hinder
proper metabolism and decrease the effectiveness of a compound
like NPC1161B. A more practical approach to treat infected
mosquitoes is through the use of modified sugar baits containing
the drug. Attractive-toxic sugar baits are currently used to
deliver insecticides like ivermectin, and they are inexpensive and
effective at killing both male and female mosquitoes (Zhu et al.,
2017; Sissoko et al., 2019). However, there is concern over the use
of insecticides in these baits due to the emergence of resistance in
mosquito populations (Tenywa et al., 2017; Maia et al., 2018). An
appealing alternative would be to use these baits to deliver drugs
that target the pathogen instead of the mosquito. Ingestion of
NPC1161B from a sugar meal would likely result in metabolism
via the midgut, as was seen in our study. This delivery method
is more practical than pretreating surfaces but would require
further development to ensure drug stability in the field.
In addition to the tolerability profile, it would be ideal for
a transmission-blocking drug to have efficacy against not only
P. falciparum but also against the other human malarial parasites.
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METHODS
Mosquito Colonies

The An. stephensi (SDA500) and An. gambiae (KEELE) colonies
were raised at 26°C under 70% humidity with equal day–night
conditions. Adult mosquitoes were sustained with sucrose
and water.

P. falciparum Standard Membrane
Feeding Assay

P. falciparum (NF54) gametocyte cultures were grown under
hypoxic conditions by combining 0.5% asexual mix with
4% hematocrit blood in RPMI culture media with HEPES,
hypoxanthine, glutamine, and 10% human serum, which was
changed daily during culturing. From day 15 through day 18 postseeding, the cultures could be used to infect mosquitoes using
the standard membrane feeding assay. Approximately 80–100
An. stephensi were aspirated into cups and starved overnight to
ensure blood feeding. Mosquitoes were at least 4 days old after
emerging on the day of infection to optimize feeding but no older
than 8 days. All materials used to prepare cultures were warmed to
37°C. Pre-washed blood and culture were centrifuged at 1,800 × g
for 4 min with the brake on 4 to pellet the uninfected RBCs. The
RPMI was aspirated from the packed RBCs, and heat-inactivated
human serum (HIHS) was added to 50% hematocrit, all while
keeping blood at 37°C. Infected packed RBCs were diluted to
0.3% gametocytemia with 50% hematocrit uninfected blood.
Infectious blood remained at 37°C, and 150 μl of infectious blood
was added to each sealed feeder. The mosquitoes were allowed
to feed for a minimum of 45 min. When most mosquitoes
had visibly fed, those that did not feed were removed, and the
remainder were provided with sucrose and water along with a
saturated cotton ball and filter paper that allowed for oviposition
so that the mosquitoes could take another blood meal to receive
the drug on day 4 post-infection. Mosquitoes were maintained at
26°C with 70% humidity.
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Administering NPC1161B To Infected
Mosquitoes

at 4°C. Midguts were incubated with 3% bovine serum albumin
(BSA) and 0.1% Triton-X-100 to block and permeabilize for 1 h
at room temperature or overnight at 4°C. Samples were washed
in PBS and incubated overnight at 4°C in a 1:1,000 dilution of
0.5 mg/ml mouse anti-P. falciparum circumsporozoite protein
[PfCSP; 2A10; MRA183A, Malaria Research and Reference
Reagent Resource Center (MR4), Bei Resources], in 3% BSA.
Following incubation with the primary antibody, midguts were
washed in PBS and incubated for 1 h in a 1:1,000 dilution of 2 mg/
ml Alexa Fluor goat anti-mouse 594 antibody (Life Technologies,
Frederick, MD) in 3% BSA while being protected from light.
Following incubation with the secondary antibody, midguts
were washed in PBS, deposited on a slide in a drop of ProLong
Diamond Antifade Reagent with DAPI (Life Technologies,
Frederick, MD), and covered with a 22 × 22 mm coverslip.
Slides were viewed and imaged using a Nikon Upright E800,
Nikon 90i, or Zeiss Axioskop2 microscope and the GNU Image
Manipulation Program (GIMP).

A 10 mM stock of NPC1161B in carrier consisting of 100 μl of
DMSO, 5 μl of TWEEN-80, 400 μl of PEG-400, and 495 μl of
sterile de-ionized water was prepared along with the control
solution of carrier alone. From the 10 mM NPC1161B stock, 1 μl
was added to 1 ml of 50% hematocrit uninfected blood in HIHS
for a final concentration of 10 μM NPC1161B. Similarly, 1 μl of
carrier control was added to 1 ml of 50% hematocrit uninfected
blood in HIHS. On day 4 post-infection with P. falciparum, the
experimental group of An. stephensi mosquitoes was fed on
300 μl of the NPC1161B-treated blood by membrane feeder.
Microscopy confirmed that direct addition of 10 μM NPC1161B
to the blood did not cause lysis of the RBCs. The control group of
An. stephensi mosquitoes was fed on 300 μl of the carrier-treated
blood by membrane feeder.
To test the blocking capabilities of NPC1161B on P. falciparum’s
oocyst stage, 1 μl of a 10 mM NPC1161B stock was added
to 1 ml of 50% hematocrit infected blood in HIHS with 0.3%
gametocytemia for a final concentration of 10 μM of NPC1161B.
Similarly, 1 μl of the carrier control was added to 1 ml of 50%
hematocrit infected blood in HIHS with 0.3% gametocytemia.
The experimental group of An. stephensi mosquitoes was fed on
300 μl of the NPC1161B-treated blood by SMFA to be infected
and treated simultaneously. The control group of An. stephensi
mosquitoes was fed on 300 μl of the carrier-treated blood by
SMFA to be infected and treated simultaneously.

Determination Of NCP1161B Metabolites

An. stephensi and An. gambiae mosquitoes were fed in an SMFA
using blood dosed with 10 µM NPC1161B or an equal volume
of drug carrier. Forty-eight hours after blood feeding, both
drug-treated and control midguts were dissected into tubes
containing cold HPLC-grade methanol (MeOH) and placed
on ice. Following dissection, metabolites were extracted from
midguts (n = 10) by sonication with a microtip probe. Sonication
parameters consisted of three pulses of 10 s with a 30 s rest period
between each, power set to 20%, and a frequency setting of 7
(Branson Sonifier 450). The samples were kept on ice throughout
the sonication process to minimize heat degradation. Following
sonication, an equal volume of cold HPLC-grade water was added
to each tube, and the sample was vortexed vigorously. Proteins
were precipitated following the addition of cold acetone and
overnight incubation at −80°C. Samples were then centrifuged at
17,000 × g for 5 min to pellet the proteins; the supernatant was
transferred to new tubes, dried using a SpeedVac, and stored at
−80°C until analysis. RBCs were also incubated with NPC1161B
alone for up to 48 h; then, metabolite extraction was performed
using the same protocol to control for potential metabolism of
the drug unrelated to the midgut.
Prior to analysis of midgut-extracted metabolites, optimization
of ion transitions for the parent compound NPC1161B was
performed using product ion mass spectrometry. A standard
solution of NPC1161B at 1 mg/ml concentration was serially
diluted into 50% MeOH, then injected onto an Agilent RRHT
C18 column (50 mm × 2.1 mm) using an Agilent 1290 Infinity
II UHPLC system consisting of binary pump, autosampler, and
temperature-controlled column compartment. The autosampler
maintained the samples at +4°C during analysis, and the column
was kept at 30°C. Solvents consisted of water + 0.1% formic acid
(FA) as solvent A and acetonitrile (ACN) + 0.1% FA as solvent
B, with a flow rate of 600 µl/min. Compounds were eluted from
the column using a gradient program as follows: 0–0.5 min 2% B,
ramping to 95% B over 3.5 min, and holding at 95% B for 0.5 min
before returning to 2% B for re-equilibration, with a total time

Oocyst Quantification

An. stephensi midguts were dissected on day 8 post-infection
and stained with 0.1% mercurochrome in PBS for 10 min. Then,
midguts were washed in PBS, arranged on a 3” × 1” microscope
slide in 12 μl of PBS and covered with a 22 × 22 mm cover slip
sealed with paraffin. The 5× objective was used with a 10× lens to
visualize the midguts and oocysts. Each midgut was imaged with
Progress Capture Pro software, ensuring oocysts in all planes
were visible. ImageJ and ProgRes CapturePro Software were
used to count oocyst number per midgut and to measure oocyst
diameter. All data were blinded. Mann–Whitney and unpaired
t-tests were run using GraphPad (GraphPad Software, Inc., La
Jolla, CA).

Sporozoite Quantification

The salivary glands of each mosquito were dissected into 100 μl
of PBS on day 14–15 post-infection. Each sample was centrifuged
at 1,200 × g for 3 min and homogenized to release the sporozoites
from the salivary glands using a sterile micro-pestle. Samples
were vortexed and centrifuged again. Sporozoites were counted
blindly on a hemocytometer by averaging two fields. Kruskal–
Wallis and two-tailed t-tests were run using GraphPad.

Immunofluorescence Assay Of
Whole Midguts

An. stephensi midguts were dissected on day 12 post-infection
and fixed in 4% paraformaldehyde for 1 h on ice or overnight
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of 5 min. Eluted compounds were analyzed by an Agilent 6495
triple quadrupole mass spectrometer (QqQ-MS). The system
was operated in positive ion mode, with a source temperature
of 250°C, gas flow of 15 L/min, sheath gas temperature of 350°C,
sheath gas flow of 11 L/min, and capillary and nozzle voltages of
3,500 V and 500 V, respectively. Product ion scan mode was used,
with the optimization of parameters for collision energy and
selection of fragment ions determined using Agilent Optimizer
Software. The first quadrupole was set to select for the precursor
ion 434.2 m/z with an isolation width of 0.7 m/z, while the third
quadrupole was set to full scan mode between 35 and 500 m/z.
The entire system was controlled using Agilent MassHunter
Acquisition software.
Analysis of metabolites extracted from midguts was performed
using the same system as described above, with the following
changes. A Waters Acquity HSS C18 column (150 mm × 2.1 mm)
was used, the column was maintained at 50°C, and the following
gradient was used: 0–2 min 2% B, ramping to 95% B over 24
min, holding at 95% B for 2 min before returning to 2% B for
re-equilibration, with a total time of 30 min. The solvent system
and flow were as described above. Source parameters were the
same as above, but precursor ion scan mode was used. The first
quadrupole was set to full scan mode between 100 and 600 m/z,
while the third quadrupole was set to selectively monitor three
ions representing fragments of the parent compound NPC1161B
(203.2, 215.1, and 334.0 m/z, respectively). CID with N2 gas was
done at 42 eV, with a cell accelerator voltage of 5 V, as optimized
previously on the standard. A dwell time of 200 ms for each
product ion was used, and the fragmenter was fixed at 380 V.
High resolution mass spectrometry analysis for NPC1161B
and midgut metabolites was performed using the same LC
system, column, and gradient as above. Eluted compounds were
analyzed by an Agilent 6550 quadrupole time-of-flight mass
spectrometer (Q-ToF-MS). The system was operated in positive
ion mode, with the same source parameters as described above.
Targeted MS/MS was used to collect fragmentation data with
the following parameters: MS1 data were collected from 50 to
1,000 m/z at 1 spectra/s, and MS2 data were collected from 35 to
500 m/z at 3 spectra/s. Fragmentation was done by CID at 42 eV
as before, with the quadrupole isolation width set to 1.3 m/z.
Both 24- and 48-h post-blood feedings were analyzed, but we
found that the parental compound NPC1161B remained in high
abundance after 24 h. We therefore focused our analyses at 48 h,

which coincides with the physiological completion of midgut
blood digestion and is likely when the majority of NPC1161B
metabolites can be found in the midgut.
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